Prosecution Insights
Prosecution Insights
25 pending office actions • 18 art units • 24 examiners • 0 of 25 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (8%) |
| §103 only | 7 (28%) |
| §102 only | 1 (4%) |
| §112 only | 2 (8%) |
| Double-patenting + other | 3 (12%) |
| Multi-statute (no §101) | 9 (36%) |
| No statute on record | 1 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DACE DENITO, ALEXANDRA GERALDINE | 2 | 60.3% | +35.7% |
| SINGH, ANOOP KUMAR | 1 | 42.8% | +67.4% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
| MIANO, JOSEPH PAUL | 1 | 36.1% | +64.0% |
| LAU, JONATHAN S | 1 | 63.9% | -18.1% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.7% |
| NGUYEN, NGOC-ANH THI | 1 | 30.0% | +48.4% |
| TATGE, LEXUS MARC | 1 | 50.0% | +100.0% |
| HAMA, JOANNE | 1 | 25.1% | +38.8% |
| HUDSON, AMY ROSE | 1 | 75.0% | +11.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578744 | METHODS OF TREATING NEPHROTIC SYNDROME | HEASLEY, MEGHAN CHRISTINE | 6d |
| 18905388 | METHODS AND MATERIALS FOR GALGT2 GENE THERAPY | CANDELARIA, JULIANA IRENE | — |
| 18712159 | CHIMERIC HSV EXPRESSING HIL21 TO BOOST ANTI-TUMOR IMMUNE ACTIVITY | MIANO, JOSEPH PAUL | — |
| 18573684 | METHODS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) | LAU, JONATHAN S | — |
| 18286923 | MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY | VIVLEMORE, TRACY ANN | — |
| 18281115 | USE OF TAMOXIFEN AND RELATED COMPOUNDS TO REDUCE BREAST IMPLANT CAPSULE FORMATION AND CAPSULAR CONTRACTURE | NGUYEN, NGOC-ANH THI | — |
| 18034668 | COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM | HAMA, JOANNE | — |
| 18246594 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | HUDSON, AMY ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19298798 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | SINGH, ANOOP KUMAR | 7d |
| 18712159 | CHIMERIC HSV EXPRESSING HIL21 TO BOOST ANTI-TUMOR IMMUNE ACTIVITY | MIANO, JOSEPH PAUL | — |
| 18281115 | USE OF TAMOXIFEN AND RELATED COMPOUNDS TO REDUCE BREAST IMPLANT CAPSULE FORMATION AND CAPSULAR CONTRACTURE | NGUYEN, NGOC-ANH THI | — |
| 18279169 | PRODUCTS AND METHODS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES USING CRISPR-CAS9 TO CORRECT DMD EXON DUPLICATIONS | DACE DENITO, ALEXANDRA GERALDINE | — |
| 18274327 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | TATGE, LEXUS MARC | — |
| 18038878 | COMPOSITIONS AND METHODS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) | DACE DENITO, ALEXANDRA GERALDINE | — |
| 18034668 | COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM | HAMA, JOANNE | — |
| 18246594 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | HUDSON, AMY ROSE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 4 |
| 1638 | 2 |
| 1631 | 2 |
| 1632 | 1 |
| 1693 | 1 |
| 1624 | 1 |
| 1637 | 1 |
| 1645 | 1 |
| 1656 | 1 |
| 1798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19298798 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | SINGH, ANOOP KUMAR | 1632 | §112Other | Final Rejection | 7d | Pending | Aug 13, 2025 |
| 18905388 | METHODS AND MATERIALS FOR GALGT2 GENE THERAPY | CANDELARIA, JULIANA IRENE | — | §103 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18712159 | CHIMERIC HSV EXPRESSING HIL21 TO BOOST ANTI-TUMOR IMMUNE ACTIVITY | MIANO, JOSEPH PAUL | — | §102§103§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18573684 | METHODS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) | LAU, JONATHAN S | 1693 | §102§103 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18286923 | MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY | VIVLEMORE, TRACY ANN | 1638 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18281115 | USE OF TAMOXIFEN AND RELATED COMPOUNDS TO REDUCE BREAST IMPLANT CAPSULE FORMATION AND CAPSULAR CONTRACTURE | NGUYEN, NGOC-ANH THI | 1624 | §102§103 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18279169 | PRODUCTS AND METHODS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES USING CRISPR-CAS9 TO CORRECT DMD EXON DUPLICATIONS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §102 | Non-Final OA | — | Pending | Aug 28, 2023 |
| 18274327 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | TATGE, LEXUS MARC | 1637 | §102§103§112DP | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18038878 | COMPOSITIONS AND METHODS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | May 25, 2023 |
| 18034668 | COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM | HAMA, JOANNE | 1645 | §103§112DP | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18246594 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | HUDSON, AMY ROSE | 1636 | §102§103§112 | Final Rejection | — | Pending | Mar 24, 2023 |
| 17910992 | NK CELLS AND USES THEREOF FOR TREATMENT OF MICROBIAL INFECTIONS | WILSON, MICHAEL C | 1638 | Other | Final Rejection | — | Pending | Sep 12, 2022 |
| 17426993 | ADENO-ASSOCIATED VIRUS DELIVERY OF CLN6 POLYNUCLEOTIDE | SPENCER, ANDREA LYNNE MORRIS | 1631 | §102§103DP | Final Rejection | — | Pending | Jul 22, 2022 |
| 17786721 | OPTIMIZED GENE THERAPY FOR TARGETING MUSCLE IN MUSCLE DISEASES | CHOWDHURY, IQBAL HOSSAIN | 1656 | §103 | Final Rejection | 36d overdue | Pending | Jun 17, 2022 |
| 17776912 | SYSTEMS AND METHODS PRODUCING SEEDED GRAFTS | GORDON, BRIAN R | 1798 | §102§103§112 | Final Rejection | — | Pending | May 13, 2022 |
| 17632263 | EXON 44-TARGETED NUCLEIC ACIDS AND RECOMBINANT ADENO-ASSOCIATED VIRUS COMPRISING SAID NUCLEIC ACIDS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES | REGA, KYLE THOMAS | 1636 | §103§112 | Non-Final OA | — | Pending | Feb 02, 2022 |
| 17431270 | USE OF PLASMA MEMBRANE PARTICLES, LIPOSOMES, AND EXOSOMES TO ASSAY IMMUNE CELL POTENCY | SKOKO III, JOHN JOSEPH | 1600 | §103Other | Non-Final OA | — | Pending | Aug 16, 2021 |
| 17272194 | GENE THERAPY FOR THE TREATMENT OF GALACTOSEMIA | NGUYEN, QUANG | 1631 | §103 | Final Rejection | — | Pending | Feb 26, 2021 |
| 17265505 | PRENATAL PROBIOTIC FORMULATIONS | MISHRA, DEEPA | 1657 | §103Other | Non-Final OA | 96d overdue | Pending | Feb 02, 2021 |
| 17256640 | COMPOSITIONS AND METHODS FOR MEDIATING EPS | SIMMONS, CHRIS E | 1622 | §103 | Non-Final OA | 75d | Pending | Dec 28, 2020 |
| 18290772 | INHIBITING INTRACELLULAR PATHOGENS | MOU, LIYUAN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Jan 20, 2024 |
| 18578744 | METHODS OF TREATING NEPHROTIC SYNDROME | HEASLEY, MEGHAN CHRISTINE | 1626 | §102§103 | Final Rejection | 6d | Pending | Jan 12, 2024 |
| 18288008 | EVALUATION OF PATIENTS WITH CYSTIC FIBROSIS USING SWEAT | WECKER, JENNIFER | 1797 | §101§103 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18483090 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR USING HLA-F | BRETZ, COREY LANE | 1635 | §112 | Non-Final OA | — | Pending | Oct 09, 2023 |
| 17018681 | UNIVERSAL DONOR SELECTION METHOD TO IDENTIFY NK-CELL-DONORS | DIBRINO, MARIANNE | 1641 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial